Rabinowitz Matthew sold $698K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 1,718 shares of Natera, Inc. (NTRA) at $406.00 ($0.70M total) on 2026-10-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Oct 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale adds a small amount of supply to the market, potentially nudging the stock lower in the short term.

02

Market read

Primary insider sale filing; modest relevance for short‑term traders.

03

What to watch

The 10b5‑1 plan pre‑arranged the sale, reducing the likelihood of insider concern.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Oct 27, reported Oct 29

Background

SEC Form 4 filing discloses an insider transaction by Natera's Executive Chairman.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Executive Chairman Matthew Rabinowitz sold 1,718 NTRA shares for $697,508 via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Sale size is modest relative to holdings, but insider sales often trigger short‑term caution.

Market effects

Minimal impact on the broader genetic‑testing sector.

No significant regional effect.

Limited to investors tracking Natera.

Counterpoint

The sale could be a routine liquidity event and not indicative of negative fundamentals.

Key entities

  • Natera, Inc.

    Genomics testing company (NASDAQ: NTRA).

  • Matthew Rabinowitz

    Executive Chairman of Natera.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.